Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions

Slipicevic, Ana; Holth, Arild; Hellesylt, Ellen; Tropé, Claes G.; Davidson, Ben; Flørenes, Viví Ann

doi:10.1016/j.ygyno.2014.07.102

Cited by 60 publications

(46 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, WEE1 mRNA expression was significantly increased in CRC tissues compared with the corresponding adjacent normal tissues and the upregulation of WEE1 mRNA was observed in 41.9% of patients with CRC (18/43 cases). The upregulation of WEE1 mRNA in CRC is not only in agreement with the expression pattern of WEE1 in other human malignancy tissues, including HCC (16)(17)(18)(19), but also suggests WEE1 upregulation as a common event during the carcinogenesis of human malignancies, including CRC.…”

Section: Discussionsupporting

confidence: 77%

“…Although the upregulation of WEE1 has been observed in several human malignancies, including in HCC and melanoma, and in numerous types of tumor cell lines including glioblastoma and breast cancer (16)(17)(18)(19), the data regarding the expression pattern of WEE1 in human CRC remains limited. Using a cDNA array and semi-quantitative RT-PCR, Backert et al (26) identified that WEE1 expression was decreased in human colon cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

“…These results are consistent with results obtained from studies on malignant melanoma, increasing evidence for the potential prognostic value of high WEE1 expression to CRC. Slipicevic et al (19) identified WEE1 as a novel independent prognostic marker of poor survival for ovarian carcinoma patients following chemotherapy by multivariate Cox analysis. Therefore, the present study also established a Cox regression model, and this model indicated high WEE1 expression to be an independent risk factor for the prognosis of patients with CRC.…”

Section: Wee1 Immunostaining Scores ---------------------------------mentioning

confidence: 99%

“…WEE1 is therefore a critical G2 checkpoint regulator that induces interphase and prevents the initiation of mitosis (15). Previous studies have shown that WEE1 expression is increased in various types of human malignancies including melanoma and vulvar squamous cell, ovarian and hepatocellular carcinoma (HCC) (16)(17)(18)(19). Elevated WEE1 expression is also documented in glioblastoma and breast cancer cells, and the inhibition of WEE1 in these cells results in suppressed cellular proliferation and increased apoptosis (20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. WEE1 is a serine/threonine protein kinase that inactivates cell division cycle 2 and is therefore a critical cell cycle regulator. Increased WEE1 expression has been observed in numerous types of human malignancies, including hepatocellular carcinoma and melanoma. WEE1 inhibition also results in evident anti-tumor effects in several human tumor cells including colon cancer cells, suggesting WEE1 as a potential therapeutic target for the treatment of cancer. However, the expression pattern of WEE1 in colorectal cancer (CRC) remains unclear. In the present study, WEE1 mRNA expression in 43 cases of CRC tissues matched with adjacent normal tissues was determined by reverse-transcription quantitative polymerase chain reaction. The results demonstrated that WEE1 mRNA expression was significantly increased in CRC tissues and that this upregulation correlated significantly with hepatic metastasis, distant metastasis and high tumor node metastasis (TNM) stage of CRC. Additionally, WEE1 protein in 102 CRC tissue samples was detected by immunohistochemistry, and positive staining of WEE1 was identified in more than half of patients with CRC. WEE1 staining scores were also observed to be associated with distant metastasis and high TNM stage of CRC. In addition, patients with CRC with high WEE1 staining score (2+ or 3+) exhibited either poorer overall survival or poorer disease-free survival compared with those with low WEE1 staining score (0 or 1+). The multivariable Cox model also identified a high WEE1 staining score as well as high TNM stage to be independent prognostic factors for CRC. In conclusion, WEE1 upregulation is associated with a high degree of malignancy and poor prognosis of CRC, suggesting WEE1 as a potential prognostic biomarker for CRC.

show abstract

Section: Discussionsupporting

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Wee1 Immunostaining Scores ---------------------------------mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The inhibitory phosphorylation of Tyr15 on CDK1 by WEE1 impedes CDK1/cyclin B function, resulting in cell-cycle arrest at G2-M and DNA-damage repair. [1] WEE1 is expressed at high levels in a number of cancers and is associated with poor clinical outcome, [5] suggesting that these cancers are heavily dependent on this mechanism for survival.…”

Section: Introductionmentioning

confidence: 99%

Development of Potent Pyrazolopyrimidinone‐Based WEE1 Inhibitors with Limited Single‐Agent Cytotoxicity for Cancer Therapy

2018

View full text Add to dashboard Cite

WEE1 kinase regulates the G /M cell-cycle checkpoint, a critical mechanism for DNA repair in cancer cells that can confer resistance to DNA-damaging agents. We previously reported a series of pyrazolopyrimidinones based on AZD1775, a known WEE1 inhibitor, as an initial investigation into the structural requirements for WEE1 inhibition. Our lead inhibitor demonstrated WEE1 inhibition in the same nanomolar range as AZD1775, and potentiated the effects of cisplatin in medulloblastoma cells, but had reduced single-agent cytotoxicity. These results prompted the development of a more comprehensive series of WEE1 inhibitors. Herein we report a series of pyrazolopyrimidinones and identify a more potent WEE1 inhibitor than AZD1775 and additional compounds that demonstrate that WEE1 inhibition can be achieved with reduced single-agent cytotoxicity. These studies support that WEE1 inhibition can be uncoupled from the potent cytotoxic effects observed with AZD1775, and this may have important ramifications in the clinical setting where WEE1 inhibitors are used as chemosensitizers for DNA-targeted chemotherapy.

show abstract

The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer

Zeng

Wang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions

Cited by 60 publications

References 34 publications

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer

Development of Potent Pyrazolopyrimidinone‐Based WEE1 Inhibitors with Limited Single‐Agent Cytotoxicity for Cancer Therapy

The lncRNA XIST/miR‐125b‐2‐3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer

Contact Info

Product

Resources

About